Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.48 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4648682 | 0.89 | TSHR (0.47) | ATMPOLBSMN1; SMN2USP2TSHR | |
| SCHEMBL1367859 | 0.88 | POLB (0.57) | POLBSMN1; SMN2USP2TSHRKMT2A | |
| SCHEMBL28507132 | 0.87 | CA1 (0.43) | ATMPOLBSMN1; SMN2USP2HTT | |
| SCHEMBL12615115 | 0.87 | POLB (0.59) | POLBSMN1; SMN2USP2TSHRKMT2A | |
| SCHEMBL17394350 | 0.86 | KCNH2 (0.44) | ATMPOLBSMN1; SMN2USP2LMNA | |
| SCHEMBL3077040 | 0.85 | POLB (0.56) | POLBTSHRHTTLMNA | |
| SCHEMBL4007349 | 0.85 | LMNA (0.59) | POLBLMNA | |
| SCHEMBL26923874 | 0.84 | KMT2A (0.44) | POLBKMT2AMEN1L3MBTL1LMNA | |
| SCHEMBL4003103 | 0.84 | MEN1 (0.53) | POLBSMN1; SMN2KMT2AHTTMEN1 | |
| SCHEMBL15306961 | 0.84 | POLB (0.52) | POLBSMN1; SMN2TSHRKMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092032-A1 | DEOXYCYTIDINE KINASE INHIBITORS | INSTITUT JEAN PAOLI & IRENE CALMETTES CENTRE REGIONAL DE LUTTE CONTRE LE CANCER (FR) | 2025-03-20 | — | — | US | disclosed |
| CN-116162087-B | HPK 1 and/or LCK kinase regulator, preparation method and application thereof | 杭州医学院 | 2024-07-23 | — | — | CN | disclosed |
| CN-117447470-A | Pyrrolopyridine derivative as HPK1 inhibitor, preparation method and application thereof | 杭州医学院 | 2024-01-26 | — | — | CN | disclosed |
| CN-117447479-A | Pyrrolopyrazine derivative of targeted tumor immune kinase, preparation method and application thereof | 杭州医学院 | 2024-01-26 | — | — | CN | disclosed |
| CN-116162087-A | HPK 1 and/or LCK kinase regulator, preparation method and application thereof | 杭州医学院 | 2023-05-26 | — | — | CN | disclosed |
| US-20220153729-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220153729-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-05-19 | — | — | US | disclosed |
| US-11084804-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-08-10 | — | — | US | disclosed |
| US-11084804-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-08-10 | — | — | US | disclosed |
| US-11040978-B2 | Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-06-22 | — | — | US | disclosed |
| US-20080113985-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-15 | — | — | US | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| WO-2007056341-A1 | HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-18 | — | — | WO | disclosed |
| EP-1768986-A2 | FURANOPYRIMIDINES | Amgen Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20060258670-A1 | New phenylpyridylpiperazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-11-16 | — | — | US | disclosed |
| EP-1721897-A1 | Phenylpyridinylpiperazin derivatives, the process to make them and the pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2006-11-15 | — | — | EP | disclosed |
| US-20060040961-A1 | Furanopyrimidines | AMGEN INC. | 2006-02-23 | — | — | US | disclosed |
| WO-2006004658-A2 | FURANOPYRIMIDINES | AMGEN INC. (US) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258670-A1 | New phenylpyridylpiperazine compounds | HRH4, HRH3, HRH2 | ATM 3935/4885POLB 4224/4885SMN1; SMN2 3085/4885 |
| US-20060040961-A1 | Furanopyrimidines | TYMS, IDO1, NFATC1 | ATM 2293/4885POLB 1688/4885SMN1; SMN2 1350/4885 |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | CFTR, ABCC8, ABCB1 | ATM 2869/4885POLB 2585/4885SMN1; SMN2 4663/4885 |
| US-11084804-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | ATM 3468/4885POLB 2480/4885SMN1; SMN2 4779/4885 |
| US-20220153729-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ATM 3468/4885POLB 2480/4885SMN1; SMN2 4779/4885 |
| US-20080113985-A1 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | ATM 3468/4885POLB 2480/4885SMN1; SMN2 4779/4885 |
| US-11040978-B2 | Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof | MKNK2, MKNK1, MAPKAPK2 | ATM 273/4885POLB 585/4885SMN1; SMN2 555/4885 |
| US-20250092032-A1 | DEOXYCYTIDINE KINASE INHIBITORS | DCK, DTYMK, TYMP | ATM 415/4885POLB 419/4885SMN1; SMN2 4314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.